Destiny Pharma Says NTCD-M3'S Clinical, Commercial Opportunity Confirmed by U.S. Research

By Anthony O. Goriainoff

Destiny Pharma PLC said Monday the clinical and commercial opportunity of its NTCD-M3 asset, a drug for the treatment of clostridioides difficile infections, was confirmed by a U.S. research study and new market research.

The London-listed clinical-stage biotechnology company said the results of a study undertaken by the U.S. Department of Veterans Affairs confirmed NTCD-M3's ability to colonize the gut after antibiotic administration. The company said these findings strengthened its market opportunity, as they support its use following commonly used antibiotic treatments.

The company also said that market research undertaken in Europe and North America reinforced the asset's clinical support and market potential.

"There is significant value potential in our NTCD-M3 asset, and we look forward to providing further updates on the regulatory and development plans throughout 2022," Chief Executive Neil Clark said.

Shares at 0835 GMT were up 1.50 pence, or 1.5%, at 100.50 pence.

Write to Anthony O. Goriainoff at anthony.orunagoriainoff@dowjones.com

(END) Dow Jones Newswires

January 24, 2022 03:59 ET (08:59 GMT)

Destiny Pharma (LSE:DEST)
Historical Stock Chart
From Mar 2024 to Apr 2024